Patent US4364922A successfully refreshed from Google Patents.
US4364922A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
Assignee: UVA Licensing and Ventures Group
•
Filing: 1980-10-14
•
Granted: 1982-12-21
•
Expires: 2000-10-14
Abstract
Abstract A method of relieving atrioventricular conduction block by administering to a human or animal an effective amount of an adenosine antagonist that competitively inhibits adenosine or that reduces the level of adenosine present in myocardial tissue and associated fluids. A method of diagnosing atrioventricular conduction block caused by ischemia of the heart by measuring the time delay between atrial and ventricular excitation before and after the administration of an adenosine antagonist. Specific antagonists disclosed include methylxanthines.
Inventors
- 👤 Robert M. Berne
- 👤 Luiz Belardinelli
- 👤 Rafael Rubio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:13
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/435; A61K31/46
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
54 words
A method of treating atrioventricular conduction block, comprising the steps of: administering to a human or animal with an atrioventricular conduction block an amount of an antagonist of adenosine sufficient to alleviate atrioventricular conduction block, wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 2
Independent Claim
54 words
A method of treating atrioventricular conduction block, comprising the steps of: administering to a human or animal with an atrioventricular conduction block an amount of an antagonist of adenosine sufficient to alleviate atrioventricular conduction block, wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 3
Dependent Claim
17 words
A method of treating atrioventricular conduction block according to claim 1, wherein said antagonist is a methylxanthine.
Claim 4
Dependent Claim
22 words
A method of treating atrioventricular conduction block according to claim 2, wherein said methylxanthine is administered in a dosage of 0.1-20 mg/kg.
Claim 5
Dependent Claim
22 words
A method of treating atrioventricular conduction block according to claim 2, wherein said methylxanthine is administered in a dosage of 0.45-10 mg/kg.
Claim 6
Dependent Claim
22 words
A method of treating atrioventricular conduction block according to claim 2, wherein said methylxanthine is administered in a dosage of 3-5 mg/kg.
Claim 7
Independent Claim
25 words
A method of treating atrioventricular conduction block according to claims 2, 3, 4, or 5, wherein said methyl xanthine is theophylline or a derivative thereof.
Claim 8
Dependent Claim
18 words
A method of treating atrioventricular conduction block according to claim 6, wherein said administration is by intravenous injection.
Claim 9
Dependent Claim
18 words
A method of treating atrioventricular conduction block according to claim 6, wherein said administration is by oral ingestion.
Claim 10
Dependent Claim
20 words
A method of treating atrioventricular conduction block according to claim 6, wherein said administration is by insertion of a suppository.
Claim 11
Dependent Claim
17 words
A method of treating atrioventricular conduction block according to claim 6, wherein said theophylline derivative is aminophylline.
Claim 12
Dependent Claim
18 words
A method of treating atrioventricular conduction block according to claim 10, wherein said administration is by intraveneous injection.
Claim 13
Dependent Claim
18 words
A method of treating atrioventricular conduction block according to claim 10, wherein said administration is by oral ingestion.
Claim 14
Dependent Claim
20 words
A method of treating atrioventricular conduction block according to claim 10, wherein said administration is by insertion of a suppository.
Claim 15
Dependent Claim
19 words
A method of treating atrioventricular conduction block according to claim 2, wherein said administration is a continuous intraveneous injection.
Claim 16
Dependent Claim
24 words
A method of treating atrioventricular conduction block according to claim 14, wherein said continuous intravenous injection is at a rate of about 0.45 mg/kg/hr.
Claim 17
Independent Claim
22 words
A method of treating atrioventricular conduction intravenous according to claims 14 o4 15, wherein said methylxanthine is theophylline or a derivative thereof.
Claim 18
Dependent Claim
17 words
A method of treating atrioventricular conduction block according to claim 16, wherein said theophylline derivative is aminophylline.
Claim 19
Dependent Claim
20 words
A method of treating atrioventricular conduction block according to claim 1, wherein said administration occurs concurrently with administration of atropine.
Claim 20
Dependent Claim
20 words
A method of treating atrioventricular conduction block according to claim 6, wherein said administration occurs concurrently with administration of atropine.
Claim 21
Dependent Claim
20 words
A method of treating atrioventricular conduction block according to claim 10, wherein said administration occurs concurrently with administration of atropine.
Claim 22
Dependent Claim
19 words
A method of treating atrioventricular conduction block according to claim 20, wherein 0.1-3 mg of said atropine is administered.
Claim 23
Independent Claim
50 words
A method of diagnosing atrioventricular conduction block, comprising the steps of: administering an antagonist of adenosine to a human or other animal, wherein said antagonist competitively inhibits adenosine or reduces the levels of adenosine present in myocardial tissue and associated fluids; and monitoring the delay between atrial and ventricular contraction.
Claim 24
Independent Claim
50 words
A method of diagnosing atrioventricular conduction block, comprising the steps of: administering an antagonist of adenosine to a human or other animal, wherein said antagonist competitively inhibits adenosine or reduces the levels of adenosine present in myocardial tissue and associated fluids; and monitoring the delay between atrial and ventricular contraction.
Claim 25
Dependent Claim
17 words
A method of diagnosing atrioventricular conduction block according to claim 22, wherein said monitoring is by electrocardiography.
Claim 26
Dependent Claim
17 words
A method of diagnosing atrioventricular conduction block according to claim 23, wherein said antagonist is a methylxanthine.
Claim 27
Dependent Claim
20 words
A method of diagnosing atrioventricular conduction block according to claim 24, wherein said methylxanthine is theophylline or a derivative thereof.
Claim 28
Dependent Claim
17 words
A method of diagnosing atrioventricular conduction block according to claim 25, wherein said theophylline derivative is aminophylline.
Claim 29
Independent Claim
22 words
A method of diagnosing atrioventricular conduction block according to claims 23, 24, 25 or 26, wherein said administration is by intravenous injection.
References Cited (Backward Citations)
US3317533A
Cited
US3493573A
Cited
US3928609A
Cited
US3962243A
Cited
US3989833A
Cited
US4117132A
Cited
US4144340A
Cited
US4153696A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-12-20 | 1986-06-21 | 1986-12-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-12-20 | 1990-06-21 | 1990-12-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-12-20 | 1994-06-21 | 1994-12-21 | $7700.00 | Window Closed / Lapsed |